Revance Therapeutics, Inc.·4

Feb 5, 7:53 PM ET

Foley Mark J 4

4 · Revance Therapeutics, Inc. · Filed Feb 5, 2025

Insider Transaction Report

Form 4
Period: 2025-02-03
Foley Mark J
DirectorCEO
Transactions
  • Award

    Common Stock

    2025-02-03+27,9331,024,868 total
Holdings
  • Common Stock

    (indirect: See footnote)
    110,913
Footnotes (2)
  • [F1]Represents the vesting of performance-based restricted stock units (PSUs) granted on January 31, 2023, which vest over a three-year period based on the achievement of revenue goals. On February 3, 2025, the Issuer's Compensation Committee certified a portion of the PSUs eligible to vest based on (i) the achievement of a revenue goal, measured beginning January 1, 2024 through December 31, 2024, and (ii) subject to the Reporting Person remaining in continuous service through the vesting date.
  • [F2]These shares are held by the Mark and Dana Foley, Trustees, Foley Family Trust U/A DTD 4/10/2002.

Documents

1 file
  • 4
    ownership.xmlPrimary

    4